<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papatheodoridis, G. V.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Dalekos, Gn</style></author><author><style face="normal" font="default" size="100%">Yurdaydin, C.</style></author><author><style face="normal" font="default" size="100%">Van Boemmel, F.</style></author><author><style face="normal" font="default" size="100%">Buti, M.</style></author><author><style face="normal" font="default" size="100%">Calleja, J. L.</style></author><author><style face="normal" font="default" size="100%">Chi, H.</style></author><author><style face="normal" font="default" size="100%">Goulis, J.</style></author><author><style face="normal" font="default" size="100%">Manolakopoulos, S.</style></author><author><style face="normal" font="default" size="100%">Loglio, A.</style></author><author><style face="normal" font="default" size="100%">Voulgaris, T.</style></author><author><style face="normal" font="default" size="100%">N Gatselis</style></author><author><style face="normal" font="default" size="100%">Keskin, O.</style></author><author><style face="normal" font="default" size="100%">Veelken, R.</style></author><author><style face="normal" font="default" size="100%">Lopez-Gomez, M.</style></author><author><style face="normal" font="default" size="100%">Hansen, B. E.</style></author><author><style face="normal" font="default" size="100%">Savvidou, S.</style></author><author><style face="normal" font="default" size="100%">Kourikou, A.</style></author><author><style face="normal" font="default" size="100%">Vlachogiannakos, J.</style></author><author><style face="normal" font="default" size="100%">Galanis, K.</style></author><author><style face="normal" font="default" size="100%">Idilman, R.</style></author><author><style face="normal" font="default" size="100%">Esteban, R.</style></author><author><style face="normal" font="default" size="100%">Janssen, H.</style></author><author><style face="normal" font="default" size="100%">Berg, T</style></author><author><style face="normal" font="default" size="100%">Lampertico, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B</style></title><secondary-title><style face="normal" font="default" size="100%">J Hepatol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of hepatology</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1600-0641 (Electronic)0168-8278 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND &amp;amp; AIMS: Hepatocellular carcinoma (HCC) may develop in chronic hepatitis (CHB) patients even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors and need for HCC surveillance in this setting. METHODS: Of 1951 adult Caucasians with CHB included in the PAGE-B cohort, 1427 (73%) have completed follow-up &amp;gt;5 years under therapy without HCC until year 5. Median follow-up has been 8.4 years from treatment onset. Points-based risk scores were developed to predict HCC risk after year 5. RESULTS: In years 5-12, HCC has been diagnosed in 33/1427 (2.3%) patients with cumulative incidence 2.4%, 3.2% and 3.8% at 8, 10 and 12 years, respectively. Older age or age &amp;gt;50 years, baseline cirrhosis and liver stiffness (LSM) &amp;gt;/=12 kPa at year 5 were independently associated with increased HCC risk. The HCC incidence was lower in non-cirrhotics than those with baseline cirrhosis and year-5 LSM &amp;lt;12 kPa than those with baseline cirrhosis and year-5 LSM &amp;gt;/=12 kPa. CAGE-B score was based on age at year 5 and baseline cirrhosis in relation to LSM at year 5 and SAGE-B score was based only on age and LSM at year 5 (c-index=0.809-0.814, 0.805-0.806 after bootstrap validation). Both scores offered 100% negative predictive values for HCC development in their low risk groups. CONCLUSIONS: In Caucasians with CHB, the HCC risk after the first 5 years of antiviral therapy depends on age, baseline cirrhosis status and LSM at year 5. CAGE-B and particularly SAGE-B represent simple and reliable risk scores for HCC prediction and surveillance beyond year 5 of therapy.</style></abstract><accession-num><style face="normal" font="default" size="100%">31981727</style></accession-num><notes><style face="normal" font="default" size="100%">Papatheodoridis, George VSypsa, VanaDalekos, George NYurdaydin, CihanVan Boemmel, FlorianButi, MariaCalleja, Jose LuisChi, HengGoulis, JohnManolakopoulos, SpiliosLoglio, AlessandroVoulgaris, TheodorosGatselis, NikolaosKeskin, OnurVeelken, RheaLopez-Gomez, MartaHansen, Bettina ESavvidou, SavvoulaKourikou, AnastasiaVlachogiannakos, JohnGalanis, KostasIdilman, RamazanEsteban, RafaelJanssen, Harry LABerg, ThomasLampertico, PietroengNetherlands2020/01/26 06:00J Hepatol. 2020 Jan 22. pii: S0168-8278(20)30022-2. doi: 10.1016/j.jhep.2020.01.007.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece. Electronic address: gepapath@med.uoa.gr.Department of Hygiene, Epidemiology &amp; Medical Statistics, Medical School of National and Kapodistrian University of Athens, Athens, Greece.Department of Internal Medicine, Thessalia University Medical School, Larissa, Greece.Department of Gastroenterology, University of Ankara Medical School, Ankara, Turkey.Division of Hepatology, Clinic and Polyclinic for Gastroenterology, Hepatology, Infectiology and Pneumology, University Clinic Leipzig, Germany.Hospital General Universitario Valle Hebron and Ciberehd, Barcelona, Spain.Hospital U Puerta de Hierro, IDIPHIM CIBERehd, Madrid, Spain.Department of Gastroenterology &amp; Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.4th Department of Internal Medicine, Alpharistotle University of Thessaloniki Medical School, Thessaloniki, Greece.Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 2nd Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, Hippokratio General Hospital of Athens, Athens, Greece.CRC &quot;AM e A Migliavacca&quot; Center for Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milano, Italy.Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.Department of Gastroenterology &amp; Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; Liver Clinic, Toronto Western &amp; General Hospital, University Health Network, Toronto, ON, Canada.2nd Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, Hippokratio General Hospital of Athens, Athens, Greece.Liver Clinic, Toronto Western &amp; General Hospital, University Health Network, Toronto, ON, Canada.</style></auth-address></record></records></xml>